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Abstract
Evaluation of a pathophysiological role of the interleukin-6-type cytokine oncostatin M (OSM) for human diseases has been
complicated by the fact that mouse models of diseases targeting either OSM or the OSM receptor (OSMR) complex cannot
fully reflect the human situation. This is due to earlier findings that human OSM utilizes two receptor complexes,
glycoprotein 130 (gp130)/leukemia inhibitory factor receptor (LIFR) (type I) and gp130/OSMR (type II), both with wide
expression profiles. Murine OSM on the other hand only binds to the gp130/OSMR (type II) receptor complex with high
affinity. Here, we characterize the receptor usage for rat OSM. Using different experimental approaches (knock-down of the
OSMR expression by RNA interference, blocking of the LIFR by LIF-05, an antagonistic LIF variant and stably transfected Ba/
F3 cells) we can clearly show that rat OSM surprisingly utilizes both, the type I and type II receptor complex, therefore
mimicking the human situation. Furthermore, it displays cross-species activities and stimulates cells of human as well as
murine origin. Its signaling capacities closely mimic those of human OSM in cell types of different origin in the way that
strong activation of the Jak/STAT, the MAP kinase as well as the PI3K/Akt pathways can be observed. Therefore, rat disease
models would allow evaluation of the relevance of OSM for human biology.
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Introduction
The interleukin-6-type cytokine oncostatin M (OSM) was
initially described as a cytokine with strong growth inhibitory
effects on melanoma cells [1]. Studies over the last decade have,
however, suggested that it has pleiotropic activities. Contributions
of this cytokine have been identified for hematopoietic progenitor
cell homeostasis [2,3], extrathymic T cell development [4,5],
suppression of fetal liver hematopoiesis [6,7], liver development
[8,9] and regeneration [10], angiogenesis [11], cardiac remodeling
[12] and particularly for inflammatory processes. Elevated
expression levels of human OSM are found in inflammatory
diseases like rheumatoid arthritis, psoriasis, atherosclerosis
[13,14,15,16,17] and it has been shown to induce inflammatory
genes like chemokines [18,19,20,21,22] or P-selectin [23].
Human OSM (hOSM) is mainly expressed by neutrophils,
activated macrophages, dendritic cells and T-cells [1,17,24,25] as
a 252 amino acid precursor polypeptide [26]. After cleavage of the
N-terminal signal peptide and a C-terminal pro-domain the thus
generated mature 196 amino acid protein has been shown to elicit
the highest bioactivity [27]. Meanwhile, the bovine, murine and
rat OSM orthologs have been cloned [9,28,29]. Comparison of
the gene organization of OSM with interleukin-6, granulocyte-
colony stimulatory factor and leukemia inhibitory factor (LIF)
suggested an evolutionary descent from a common ancestral gene
[30]. A particularly high homology exists to LIF [31].
So far, the receptor complexes have only been characterized for
human and murine OSM (mOSM). Unlike for other IL-6-type
cytokines, the receptor systems for OSM differ in composition
between man and mouse. Human OSM is able to utilize two
receptor complexes: the type I LIFR/gp130 heterodimer and the
type II OSMR/gp130 heterodimer [32,33]. This is in sharp
contrast to the murine ortholog which offers high affinity binding
sites only for the type II OSMR/gp130 receptor complex [34].
Consequently, in vivo studies carried out in the mouse system
cannot correctly address the physiological response to hOSM.
Additional information generated by cross-stimulation studies of
human and murine cells with OSM originating from both species
demonstrated that hOSM can efficiently activate signal transduc-
tion in murine cells, however, it utilizes only the type I LIFR/
gp130 heterodimer on these cells [34]. Therefore, reconstitution
studies using hOSM in mouse models of diseases, which mimic
rather LIF than OSM activities, have so far complicated the
evaluation of the physiological function of OSM. On the other
hand, mOSM is unable to stimulate human cells, a characteristic
shared by many other IL-6-type cytokines.
The current study characterizes the receptor complex for rat
OSM (rOSM) in order to evaluate the potential of the rat system
as more suitable model to evaluate hOSM physiology. Using
antagonistic cytokines, RNA interference to block one receptor
and stably transfected Ba/F3 cells expressing only one receptor
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complex at the time, we can show that rOSM indeed uses the type
I gp130/LIFR as well as the type II gp130/OSMR complex for
signaling. Thereby it closely resembles hOSM. Cross-stimulation
studies using human, murine and rat OSM in comparison to LIF
further delineate the species-specific receptor usage of the three
OSM orthologs.
Results
Rat OSM can stimulate human, murine and rat hepatoma
cells
Sequence analyses of the mature forms of human, mouse and
rat OSM indicate a high degree of sequence and structural
homology. Despite this homology, studies carried out by a number
of research groups in the last decade have clearly shown that
human and murine OSM signal in a species-specific manner:
hOSM can signal in human cells via two receptor complexes, the
type I gp130/LIFR or the type II gp130/OSMR [32,33] complex,
while mOSM only signals via the type II receptor complex [34].
Additionally, it was shown that hOSM activates only the type I
receptor complex (gp130/LIFR) on mouse cells and mOSM fails
to activate signaling in human cells [34]. To date the receptor
usage of rOSM is unknown.
Therefore, we first defined the signaling capacities of rOSM on
rat hepatoma cells since they express gp130, LIFR and OSMR
(data not shown). Consequently, these cells are capable of forming
the type I as well as the type II receptor complexes. Cellular lysates
were analyzed for the activation of the Jak/STAT pathway, MAP
kinase pathways and PI3K/Akt pathway (Fig. 1A). Regarding the
signaling capacities, rOSM turned out to be comparable to
hOSM, i.e. it is a strong inducer of the Jak/STAT pathway by
activating STAT1, STAT3, STAT5 (Fig. 1A, left panel) and of the
ERK1/2 MAPK pathway (Fig. 1A, top right panel). At higher
concentrations rOSM additionally activates the MAPK p38 and
the survival-promoting PI3K/Akt pathway (Fig. 1A, middle and
bottom right panels). In this aspect rOSM equals hOSM which -
unlike human LIF (hLIF)- is also a potent inducer of STAT5, p38
and Akt phosphorylation (Fig. 1B).
Murine OSM is known to be unable to stimulate cells of human
origin. To address cross-species activities of rOSM we used
hepatoma cell lines from rat, mouse and human origin (JTC-27,
Hepa1c1c7, HepG2). All three cell lines were stimulated with rat,
murine or human OSM (10 ng/ml) as well as hLIF (10 ng/ml) for
15 min. In sharp contrast to mOSM, rOSM can stimulate human
hepatoma cells (Fig. 1C, lane 10). It strongly induces the tyrosine
phosphorylation of STAT3 and -to a weaker extent- of STAT1.
However, it fails to activate ERK1/2 MAPKs. In these aspects, on
human cells rOSM mimics the activities of hLIF rather than
hOSM (Fig. 1C, compare lanes 7, 8 and 10). On mouse cells,
rOSM signals identically to mOSM (Fig. 1C, lanes 14 and 15).
Interestingly, mOSM can induce signal transduction on rat
hepatoma cells (Fig. 1C, lane 4).
Compared to stimulation of HepG2 with hOSM, the STAT1
activation mediated by rOSM on JTC-27 appeared rather weak,
which could indicate a bias of rOSM for STAT3 activation and
therefore a potential difference to hOSM. Closer inspection of
OSM receptor levels indicated, however, that HepG2 cells express
more OSMR than LIFR while in JTC-27 cells higher mRNA
levels can be detected for LIFR compared to OSMR (data not
shown). The expression level of gp130 is similar in both cell types.
Consequently, the ratio of type I to type II receptor complexes
differ in the human and rat hepatoma cell line which could be
another reason for preferences in STAT activation. Therefore, we
additionally stimulated primary dermal fibroblasts from both
species with all OSM variants. As shown in Figure 2 no difference
is observed between rOSM-mediated signaling in rat dermal
fibroblasts (RDF, Fig. 2A) and hOSM-mediated activation of
signaling pathways in human dermal fibroblasts (HDF, Fig. 2B).
Both OSM variants very potently activate STAT3, STAT1,
ERK1/2 (left panels), as well as STAT5, p38 and AKT (right
panels) if used at equal concentrations. Identical signaling activities
of rOSM are observed in neonatal rat cardiac fibroblasts (Figure
S1). Interestingly, on human cells rOSM mimics again hLIF by
only activating STAT3. Mouse OSM – as shown before in
hepatoma cells – cannot activate signaling in human cells,
however, it signals comparably to rOSM on rat cells.
Taken together, rat OSM can stimulate rat, murine and human
cells. On rat cells, it is able to activate signaling pathways
comparable to human OSM on human cells.
Rat OSM signals through the type I and type II receptor
complex on rat hepatoma cells
In order to characterize the receptor complexes used by rOSM
on rat hepatoma cells, we performed RNA interference studies to
abrogate the expression of the rat OSMR or blocked the rat LIFR
by a LIFR-specific antagonist (LIF-05, [35]).
Transfection of JTC-27 rat hepatoma cells with siRNA
targeting the rat OSMR resulted in a reduction of OSMR mRNA
levels by 80% (Fig. 3A). Specificity of the knock-down was
confirmed by stimulation of siRNA-transfected cells with hLIF.
This stimulation resulted in comparable phosphorylation of
STAT1, STAT3 and ERK1/2 in OSMR siRNA-transfected,
control siRNA-transfected or untransfected cells (Fig. 3B, lanes 2,
7, 12; quantification for control and OSMR siRNA). Thereby we
could exclude that gp130 or the LIFR were affected by the OSMR
siRNA since LIF signals exclusively via the gp130/LIFR complex.
Furthermore, no changes in protein levels for any of the signaling
molecules analyzed could be detected.
Interestingly, the activation of STAT3 and STAT1 in response
to rOSM was not significantly affected by rOSMR knock-down
(Fig. 3B, 1st and 2nd panel, lane 15). However, a strong reduction
in signaling was observed for ERK1/2 for which the phosphor-
ylation level dropped by more than 50% (Fig. 3B, 3rd panel, lane
15). This is in sharp contrast to murine OSM. Signal transduction
in response to mOSM was reduced by up to 80% in all pathways
analyzed, i.e. STAT3, STAT1 and ERK1/2 phosphorylation
(Fig. 3B, lane 14). This correlates very well with the knock-down
efficiency of the OSMR (reduction of 80%, Fig. 3A). Human
OSM on the other hand was not affected at all by the knock-down
of the rat OSMR (Fig. 3B, lane 13).
Therefore, these results gave first hints that rat OSM -in
contrast to murine OSM- can use the LIFR to transmit signals into
cells and most likely uses two signaling receptor complexes on rat
cells (rgp130/rOSMR, rgp130/rLIFR). Murine OSM uses the
type II gp130/OSMR and human OSM utilizes the type I gp130/
LIFR complex on rat cells.
To verify this hypothesis, the usage of the rat LIFR was blocked
by the LIFR antagonist LIF-05. This protein represents a mutein
of LIF in which the binding site for the LIFR (site 3) is maintained
while the binding site for gp130 (site 2) is destroyed by site-directed
mutagenesis. It has been shown that this LIF variant binds to the
LIFR, but since it cannot bind to gp130 serves as a potent
antagonist [35]. We verified this antagonistic activity of LIF-05 by
showing that it strongly impairs the signaling capabilities of LIF on
JTC-27 cells (Fig. 3C, compare lanes 3 and 4). Similarly, signaling
by human OSM is strongly impaired by pretreatment of JTC-27
cells with LIF-05 (Fig. 3C, lanes 5 and 6). This confirms the before
mentioned observation that human OSM utilizes exclusively the
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type I gp130/LIFR complex on rat cells which is equivalent to its
behavior on murine cells.
As hypothesized, activation of STAT3, STAT1 or ERK1/2 by
rOSM was hardly negatively affected by blockade of the rLIFR
(Fig. 3C, lanes 9 and 10). This clearly verifies that -in absence of
binding sites to rLIFR- rOSM can signal via activation of the
gp130/OSMR complex. The increase in ERK1/2 activation
upon rOSM stimulation of LIF-05-treated hepatoma cells (Fig. 3C,
lane 10) indicated that the OSMR offers higher affinity binding
sites for the activation of this MAPK pathway compared to the
LIFR. Since murine OSM has no known affinity for LIFR, LIF-05
was without any effect on the signal transduction by mOSM
(Fig. 3C, lane 7 and 8).
In order to provide irrevocable evidence for the above
mentioned findings that rOSM uses two receptor complexes on
rat cells, we cloned rgp130, rLIFR and rOSMR from transcripts
extracted from the rat hepatoma cells (JTC-27). The combinations
rgp130/rLIFR (type I) and rgp130/rOSMR (type II) were stably
expressed in murine Ba/F3 cells. This pre B-cell line is known to
be devoid of expression of gp130, LIFR or OSMR and is therefore
the perfect model cell line to analyze the signaling capacity of
either rgp130/rLIFR or rgp130/rOSMR in response to rOSM
stimulation. Indeed, rgp130/rOSMR as well as rgp130/rLIFR
expressing pools of Ba/F3 cells turned out to be responsive to
rOSM (Fig. 4). Interestingly, both receptor complexes allowed
statistically significant activation of the transcription factors
STAT3 and STAT1 (Fig. 4, upper and middle panel, lanes 5
and 10) as well as of the MAP kinases ERK1/2 (Fig. 4, lower
panel, lanes 5 and 10). As expected, murine OSM was unable to
stimulate the rgp130/rLIFR complex (Fig. 4, lane 9), while it
strongly induces signaling downstream of the rgp130/rOSMR
complex (Fig. 4, lane 4). On the other hand, human OSM
Figure 1. Comparison of human LIF, human, murine and rat OSM induced signal transduction in hepatoma cells. A, JTC-27 rat
hepatoma cells were treated with the indicated concentrations of rOSM for 15 min. The phosphorylation levels of STAT1, STAT3, STAT5 as well as
ERK1/2, p38 and Akt were detected via Western blot analysis. The blots were stripped and reprobed with antibodies recognizing the proteins
irrespective of their activation status. B, HepG2 human hepatoma cells were exposed to 10 ng/ml hLIF or hOSM for 15 min. Western blots detecting
the activation status of the indicated proteins were performed as described in A. C, Hepatoma cells from rat (JTC-27), human (HepG2) and murine
(Hepa1c1c7) origin were treated with 10 ng/ml hLIF, hOSM, mOSM or rOSM for 15 min. Activation of the indicated proteins was detected via Western
blot analysis as described in A. Additionally an a-tubulin loading control was included. Blots shown are representative for 3 or more experiments.
doi:10.1371/journal.pone.0043155.g001
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activates only the rat gp130/LIFR complex, but not rgp130/
rOSMR (lanes 3 and 8).
Taken together, our data indubitably demonstrate that rat
OSM has the capability to activate the type I rgp130/rLIFR as
well as the type II rgp130/rOSMR receptor complex. Thereby, its
binding properties are equivalent to those of the human OSM on
human cells and differ substantially from the murine ortholog.
Rat OSM utilizes mainly the type II receptor complexes
on murine cells
As shown in Figure 1 rOSM can induce signal transduction in
murine cells, and is therefore comparable to hOSM. From hOSM
it is known that it only utilizes the type I mgp130/mLIFR receptor
complex on mouse cells [34]. In order to determine whether the
same is true for rOSM, we transfected the murine hepatoma cell
line Hepa1c1c7 with siRNA targeting murine OSMR mRNAs.
Knock-down efficiencies similar to the rat OSMR could be
achieved (Fig. 5A, 4th panel). When we analyzed the signaling
capacities of rat, murine and human OSM, we realized that
Hepa1c1c7 cells displayed a high basal ERK1/2 phosphorylation
which was not abrogated by serum starvation. Therefore, hOSM
as well as hLIF only weakly increased the basal ERK1/2
phosphorylation, which -as expected- was not reduced by
mOSMR knock-down. Indeed, none of the hLIF or hOSM-
induced signaling pathways was significantly reduced by knock-
down of the murine OSMR (Fig. 5A, compare lanes 7, 8 with
lanes 12, 13).
Murine and rat OSM, however, clearly increased ERK
phosphorylation and knock-down of mOSMR expression almost
completely abrogated the induced increase in ERK phosphoryla-
tion (Fig. 5A, 3rd panel, compare lanes 9, 10 with lanes 14, 15).
This indicates that the rodent OSM variants induce ERK
activation via usage of the type II gp130/OSMR complex.
Regarding the STAT activation, we can clearly show that STAT1
Figure 2. Comparison of hLIF, hOSM, mOSM and rOSM activated signaling pathways in primary dermal fibroblasts. A, Rat dermal
fibroblasts (RDF) and B, human dermal fibroblasts (HDF) were treated with 10 ng/ml hLIF, hOSM, mOSM or rOSM for 15 min. The phosphorylation
levels of STAT1, STAT3, ERK1/2 as well as STAT5, p38 and Akt were detected via Western blot analysis. The blots were stripped and reprobed with
antibodies recognizing the proteins irrespective of their activation status. Additionally an a-tubulin loading control was included. Phosphorylation
intensities were quantified by chemiluminescence analysis and normalized to tubulin. Activation determined for rOSM was set to 100%. Shown are
the means (n = 3) with standard error of mean (SEM). * p,0.05, ** p,0.01, *** p,0.001 untreated vs. cytokine-treated sample.
doi:10.1371/journal.pone.0043155.g002
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tyrosine phosphorylation is also mediated by the type II receptor
complex in response to rodent OSMs since it is severely impaired
upon OSMR knock-down (Fig. 5A, 2nd panel). STAT3 activation
is also significantly reduced, however, it appears that the low
residual expression of the OSMR is sufficient to still allow decent
STAT3 activation (Fig. 5A, 1st panel).
Blockade of the murine LIFR by LIF-05 confirmed these
findings since only the signal transduction initiated by hLIF and
hOSM is strongly reduced (Fig. 5B, lanes 3 vs. 4 and 5 vs. 6), while
both rodent versions of OSM fully transduce their signals (Fig. 5B,
lanes 7 vs. 8 and 9 vs. 10).
Rat OSM utilizes mainly the type I receptor complexes on
human cells
As mentioned before, rat OSM differs substantially from murine
OSM since it can 1) utilize two receptor complexes and 2)
stimulate cells of human origin. Performing equivalent experi-
ments as before by either knock-down of the human OSMR or
blockade of the human LIFR by LIF-05 treatment, we clarified the
receptor usage for rat OSM on human cells. Knock-down of the
human OSMR by siRNA (Fig. 6A, 4th panel) did not negatively
affect rOSM-mediated signaling; it rather led to a slight increase in
rOSM-mediated STAT3 activation (Fig. 6A, 1st panel, lane 15).
Vice versa, blockade of the hLIFR by LIF-05 completely
abrogated rOSM-mediated STAT1 and STAT3 activation
Figure 3. OSMR RNA interference and LIFR antagonistic blockade elucidate rOSM receptor preference. A, JTC-27 were transfected with
control or rOSMR siRNA or left untransfected. Transfection efficiencies were analyzed by quantitative real time RT-PCR (top) and semiquantitative RT-
PCR (bottom). B, Untransfected, control siRNA and rOSMR siRNA transfected JTC-27 were treated with 10 ng/ml hLIF, hOSM, mOSM and rOSM for
15 min. Lysates were subjected to Western blot analysis using antibodies specific for the indicated proteins. The blots were stripped and reprobed
with antibodies recognizing the proteins irrespective of their phosphorylation status and with an a-tubulin antibody. Phosphorylation intensities
were quantified by chemiluminescence analysis and normalization to loading controls. Activation determined for hOSM was set to 100%. Shown are
the means (n = 3) with standard error of mean (SEM). * p,0.05, ** p,0.01, *** p,0.001 OSMR siRNA vs. control siRNA. C, JTC-27 were preincubated
with LIF-05 (50 ng/ml, 30 min) and subsequently stimulated with 10 ng/ml hLIF, hOSM, mOSM and rOSM for 15 min. The phosphorylation intensities
of indicated proteins were detected via Western blot analysis. Loading controls and quantification of chemiluminescence intensities were performed
as described in B. Shown are the means (n = 3) with standard error of mean (SEM). * p,0.05, ** p,0.01 untreated vs. LIF05-pretreated sample.
doi:10.1371/journal.pone.0043155.g003
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(Fig. 6B, compare lanes 9 and 10). Therefore, unlike in rat or
murine cells, rat OSM exclusively utilizes the hgp130/hLIFR type
I receptor complex in human cells.
To show that rat OSM completely lacks affinity for the human
OSMR, we stimulated Ba/F3 cells expressing exclusively the type
II receptor complex of hgp130/hOSMR with rat and human
OSM. While human OSM can induce proliferation of these cells
in doses as low as 0.8 ng/ml with saturation at 20 ng/ml, rat
OSM was unable to induce proliferation of Ba/F3-hgp130/
hOSMR cells irrespective of the concentration used (Fig. 6C).
Discussion
The interleukin-6-type cytokine oncostatin M is well known to
be secreted by activated neutrophils, macrophages, dendritic cells
as well as T cells [1,17,24,25] and elevated expression levels of this
cytokine have been determined in many inflammatory diseases
[13,14,15,16]. Its receptor complexes, gp130/LIFR and gp130/
OSMR, are known to be expressed on a wide variety of cells of
different origin. Its physiological function, however, is still unclear
and controversially discussed.
For example, during inflammation OSM has been attributed
pro- as well as anti-inflammatory activities. Administration of
recombinant human OSM to LPS-pretreated mice strongly
reduced the LPS-induced TNFa secretion and prolonged the
survival of these animals [36]. Furthermore, the degree of joint
destruction was reduced in these mice indicative of an anti-
inflammatory activity of OSM [36]. On the other hand, intra-
articular administration of adenoviral-encoded OSM strongly
induced a rheumatoid arthritis-like phenotype in mice [37] and
administration of neutralizing antibodies against OSM strongly
attenuated the symptoms of collagen- and pristane-induced
arthritis arguing for a strong pro-inflammatory role [38]. Similarly,
inhalation of adenovirus particles encoding mOSM resulted in
exacerbated infiltration of eosinophils into the lung of infected
mice [19].
One explanation for these controversial findings might originate
from the fact that OSM derived from different species was used to
stimulate mouse cells. The study claiming an anti-inflammatory
role of OSM made use of recombinant human OSM injected into
mice [36] while a number of studies pointing to a more pro-
inflammatory role administered murine OSM in murine cells
[19,37,38]. On the molecular level this usage of OSM from
different species results in the stimulation of different receptor
complexes: human OSM exclusively binds to the type I gp130/
LIFR system in mouse cells; murine OSM, however, exclusively
activates the type II gp130/OSMR system. Indeed, a recent study
with mice overexpressing bovine, human and murine OSM by
retroviral gene transfer confirmed this receptor usage and
demonstrated that mice overexpressing bovine or human OSM
displayed a LIF-like phenotype, while murine OSM overexpress-
ing mice differed significantly in their phenotype [39]. Strictly
speaking, none of these studies was able to analyze a situation like
it is found in the human system, in which OSM uses both receptor
systems. Actually, all three mouse models exhibit rather mild
phenotypes which are in sharp contrast to all studies applying
retroviral or adenoviral OSM or all in vitro studies which showed
exacerbated inflammatory gene expression upon OSM stimula-
tion. Therefore, there is a demand for animal models reflecting the
human situation more precisely.
This study provides evidence that rat OSM is identical to
human OSM with respect to its receptor usage: like the human
ortholog rat OSM has the capability to signal via both, the type I
gp130/LIFR as well as the type II gp130/OSMR receptor
complex. Knockdown of the rat OSMR by more than 80% has
almost no effect on the STAT1 or STAT3 activation by rOSM in
rat hepatoma cells (Fig. 3B) which is indicative of the gp130/LIFR
usage in absence of available OSMR. This is in sharp contrast to
the mouse ortholog, for which knockdown of the OSMR almost
completely abrogates signaling (Fig. 3B). Interestingly, activation
of the MAP kinases ERK1 and ERK2 in response to rOSM is
Figure 4. Verification of dual receptor usage by rOSM in stably transfected Ba/F3 cells. Ba/F3 cells stably expressing rgp130/rLIFR or
rgp130/rOSMR were treated with 10 ng/ml hLIF or 20 ng/ml hOSM, mOSM or rOSM for 15 min. Lysates were subjected to Western blot analysis using
antibodies specific for the indicated proteins. Loading controls were performed as described in 3B. Phosphorylation intensities were quantified by
chemiluminescence analysis and normalized to tubulin. Activation determined for rOSM was set to 100%. Shown are the means (n = 3 for STAT1 and
ERK, n = 6 for STAT3) with standard error of mean (SEM). * p,0.05, ** p,0.01, *** p,0.001 untreated vs. cytokine-treated sample, # p,0.05, ##
p,0.01, ### p,0.001 for rOSM vs. either hLIF/hOSM or mOSM.
doi:10.1371/journal.pone.0043155.g004
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much more severely affected by the knock-down of the OSMR
than the activation of the STAT transcription factors. This led us
to hypothesize that the LIFR offers only much lower affinity
binding sites for adapter molecules linking the receptor to MAPK
activation.
On the other hand, rOSM also appears to use the gp130/
OSMR complex since blockade of the LIFR binding sites by the
Figure 5. Effects of OSMR knock-down and LIFR blockade for the receptor preference of LIF and OSM in murine cells. A,
Untransfected, control and mOSMR siRNA-transfected Hepa1c1c7 cells were treated with 10 ng/ml hLIF, hOSM, mOSM and rOSM for 15 min.
Phosphorylation levels of the indicated proteins as well as quantification were detected as described in legend to Figure 3B.* p,0.05, ** p,0.01 and
*** p,0.001 OSMR siRNA vs. control siRNA (n = 4). B, Hepa1c1c7 were, as indicated, pre-incubated with LIF-05 (50 ng/ml, 30 min) and subsequently
stimulated with 1 ng/ml hLIF, 10 ng/ml hOSM, mOSM or rOSM for 15 min. The phosphorylation intensities of the indicated proteins were analyzed
and quantified as described in legend to Figure 3B (n = 2).
doi:10.1371/journal.pone.0043155.g005
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mutant LIF protein LIF-05, which still binds the LIFR with high
affinity via its site 3, but cannot bind gp130 due to point mutations
in the site 2 of the cytokine [35], does not affect the signaling
capacity of rat OSM (Fig. 3C). The efficiency of LIF-05 in
blocking access to the LIFR for other cytokines was proven by the
finding that STAT as well as ERK activation in response to both,
LIF itself as well as hOSM is strongly impaired upon pretreatment
of rat hepatoma cells with LIF-05 (Fig. 3C). Interestingly, blockade
of the LIFR by LIF-05 resulted in an even slightly enhanced ERK
activation in response to rOSM (Fig. 3C, quantification right
panel). Therefore, forcing the cytokine into a type II receptor
usage appears to strengthen activation of the ERK MAPK
cascade. The OSMR appears to be a more potent activator of this
pathway which might be due to the conserved Shc adapter binding
site (Y861 in hOSMR) in the cytoplasmic region. This tyrosine
motif and the Shc adapter protein were shown to be important for
the OSMR-mediated activation of the MAPK pathway in
response to human OSM [40]. The LIFR requires the tyrosine
phosphatase SHP-2 for the activation of ERK1/2 which besides
acting as adapter molecule might also perform strong negative
regulatory function due to its phosphatase activity [41,42].
Generation of stably transfected Ba/F3 cells which only express
the rat type I rgp130/rLIFR or the rat type II rgp130/rOSMR
Figure 6. Alterations of LIF- and OSM-induced signaling upon hOSMR knock-down or inhibition of LIFR-gp130 dimerization in
HepG2. A, Untransfected, control and hOSMR siRNA transfected HepG2 cells were exposed to 10 ng/ml hLIF, hOSM, mOSM or rOSM, respectively, for
15 min. Whole cell lysates were subjected to Western blot analysis and levels of activated STAT3, STAT1 and ERK1/2 were detected and quantified as
described in legend to Figure 3B. Shown are the means with standard error of mean (SEM). * p,0.05 OSMR siRNA vs. control siRNA (n = 3 for STAT3,
ERK1/2 and hOSM-treated STAT1, n = 2 for hLIF, mOSM, rOSM-treated STAT1). B, HepG2 were pre-incubated with LIF-05 (50 ng/ml) for 30 min and
treated with 10 ng/ml hLIF, hOSM, mOSM and rOSM for additional 15 min. The phosphorylation intensities of the indicated proteins were analyzed
and quantified as described in legend to Figure 3B (n = 2). C, Ba/F3 cells stably expressing hgp130 and hOSMR were treated with hOSM or rOSM
(0.0064–100 ng/ml) for 48 h. Afterwards, WST-1 reagent was added for 4 h. Values shown represent means (6 SEM) of absorbance measurements at
450 nm minus absorbance at 660 nm (n= 3).
doi:10.1371/journal.pone.0043155.g006
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complex gave doubtless proof that rat OSM displays high affinity
for both receptor complexes (Fig. 4).
Further characterization of the receptor usage of rOSM on cells
of other species origin led to the finding that rOSM can only use
the gp130/LIFR type I receptor complex on human cells.
Effective signal transduction in human hepatoma cells was clearly
observed (Fig. 1C, 6A, 6B), however, blockade of the hLIFR
abrogated signaling (Fig. 6B) and stably transfected Ba/F3 cells
expressing only the hgp130/hOSMR combination were unable to
grow in response to rOSM (Fig. 6C).
On mouse cells rOSM appears to mainly utilize the type II
mgp130/mOSMR complex. Knockdown of the murine OSMR
did result in a strong reduction of the OSMR mRNA and protein
levels (more than 80%), consequently, signaling of mOSM, but
also of rOSM, was significantly reduced (Fig. 5A). On the other
hand, blockade of the mLIFR by LIF-05 did not affect rat OSM
signaling at all on mouse cells (Fig. 5B).
In this study we characterized the rat OSM receptor system and
to our surprise, rOSM is more homologous to hOSM than to
mOSM in that it can signal also via both receptor complexes.
Taken into consideration that rOSM and mOSM share 60.2%
sequence identity and rOSM and hOSM only share 49% identity
(EBLOSUM62 Matrix, Gap penalty: 10.0, Extend penalty: 0.5)
this finding is rather surprising (Fig. 7B). However, analysis of the
contact sites of LIFR utilizing cytokines like ciliary neurotrophic
factor (CNTF) found surprisingly large interfaces between cytokine
and receptor [43]. Regarding the cytokine, the so-called site 3
encompasses amino acid residues of the C-terminal A helix
extending to the N-terminal AB loop, the BC loop and the C-
terminal end of the CD loop reaching into the N-terminal D helix
(Fig. 7B, underlined sequences). Sequence comparisons of the
three OSM variants indicate that the BC loop appears to be most
divergent between the species (Fig. 7B). Modeling the three OSM
structures based on the solved crystal structure of hOSM reveals
an extremely short BC loop in mOSM, while it is substantially
longer in hOSM and rOSM (Fig. 7A). Whether this region is
indeed important to allow high affinity binding to the LIFR has to
be determined by future mutagenesis experiments. Upon success-
ful identification of these amino acid residues the subsequent
mutagenesis of mOSM might allow its conversion into a variant
comparable to human OSM. Thereby the generation of a
humanized mouse model might be possible in future to evaluate
the physiological role of OSM.
Materials and Methods
Reagents, recombinant cytokines, cell lines and primary
cells
Recombinant hOSM, rOSM and mIL-3 were purchased from
Peprotech, mOSM from R&D Systems and hLIF from Sigma-
Aldrich. Recombinant LIF-05 was prepared as described previ-
ously [35] and kindly provided by Prof. Dr. J. Heath (University of
Birmingham, UK). JTC-27 rat and HepG2 human hepatoma cell
lines were purchased from the DSMZ (Braunschweig, Germany),
the Hepa 1c1c7 murine hepatoma cell line from Sigma-Aldrich.
Primary rat dermal fibroblasts were obtained from PELOBiotech
(Martinsried, Germany). All cell lines were cultured according to
the suppliers’ instructions at 5% CO2 and 37uC in water-saturated
atmosphere. All media were obtained from Invitrogen and
supplemented with 10% FCS (PAA). Ba/F3 cells stably expressing
hgp130 and hOSMR [44] were kindly provided by Prof. Dr. J.
Heath (University of Birmingham, UK) and primary human
dermal fibroblasts [45] by Prof. Dr. J.M. Baron (Department of
Dermatology and Allergology, RWTH Aachen University Hospi-
tal, Germany). Primary neonatal rat cardiac fibroblasts were
prepared as described previously [46], but cultured in Medium
199 containing 10% FCS and kindly provided by Dr. K. Lorenz
(Institute of Pharmacology and Toxicology, University of Wu¨rz-
burg, Germany).
Cell lysis and Western blotting
Upon stimulation, cells were lysed in either ice-cold Triton X-
100 lysis buffer containing 10 ml/ml Halt phosphatase inhibitor
cocktail (Thermo Fisher Scientific Inc.) or 1 x Laemmli buffer
(62.5 mM Tris-HCl, 10% glycerol, 2% sodium dodecyl sulfate
(SDS), 0.0025% bromophenol blue and 5% b-mercaptoethanol,
pH 6.8) as described previously [40]. Proteins were separated by
10% SDS-PAGE, followed by semi-dry Western blotting onto a
PVDF-membrane (Whatman, GE Healthcare). Protein detection
was conducted using the indicated antibodies and the enhanced
chemiluminescence kit (Thermo Fisher Scientific Inc.) according
to the manufacturers’ instructions. Quantification of the chemi-
luminescence signal was carried out on the FluorChemQ using the
AlphaViewH software (ProteinSimple). Equal loading of the gel
was verified by stripping the membrane in 62.5 mM Tris HCl
(pH 6.7) containing 2% SDS and 100 mM b-mercaptoethanol at
70uC for 20 minutes and redetection with antibodies recognizing
the protein irrespective of its phosphorylation status as well as by
detection of tubulin.
Antibodies
All antibodies were purchased from Cell Signaling Technology
(New England Biolabs), with the exception of the antibodies
detecting rat phospho-Tyr694-STAT5 (Signalway Antibody Co.),
STAT5 (Santa Cruz Biotechnology), tubulin (Sigma-Aldrich),
human and mouse OSMR (R&D Systems).
Small interfering RNA (siRNA) transfection
For siRNA transfections, JTC-27 cells were seeded onto 6 cm
dishes at a density of 3.06105 cells/dish and transfected using
DharmaFECT 4 (Thermo Fisher Scientific Inc.) and 100 nM
siRNA, while HepG2 and Hepa 1c1c7 were cultured on 6 wells at
2.06105 cells/well and transfected in Lipofectamine 2000
(Invitrogen) and 50 nM siRNA according to the manufacturers’
instructions. Transfection was allowed to proceed for 5 hours at
37uC, before Opti-MEM containing FCS (f.c. 10%) was added.
Cells were harvested after 28 hours (Hepa 1c1c7) or 48 hours
(HepG2 and JTC-27). Rat and murine OSMR siRNAs (OnTar-
getPlus SMARTpools) were purchased from Dharmacon (Thermo
Fisher Scientific Inc.), human OSMR siRNA from Ambion
(Applied Biosystems) and nonsilencing control siRNA (AllStars
Negative Control siRNA) from Qiagen.
Semiquantitative and quantitative RT-PCR
After treatment of cells total RNA was isolated using the
RNeasy kit (Qiagen) according to the manufacturer’s instructions.
1 mg total RNA was used for cDNA synthesis using the OneStep
RT-PCR kit (Qiagen) for semi-quantitative PCR or the Tran-
scriptor First Strand cDNA Synthesis Kit from Roche Diagnostics
for quantitative PCR. Real-time PCR was performed using the
FastStart Universal SYBR Green Master (Rox) Kit (Roche
Diagnostics) according to manufacturer’s instructions. Specific
primers were designed to be located across an exon/exon border.
Primer sequences for semi-quantitative PCR are as follows: rat
OSMR: forward 59-ATATACCAGCGCTGGCCAGG-39, re-
verse 59-AATAGTCCGAGTTGGTGCGG-39, rat GAPDH:
forward 59-TGATGACATCAAGAAGGTGG-39, reverse 59-
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TTACTCCTTGGAGGCCATGT-39. The following primers
were used for quantitative RT-PCR: rat OSMR: 59-CCTTCAT-
CAAGTGACCTTCCTT-39, reverse 59-GTAAAGGCTCCCC-
CAAGACT-39 and rat GAPDH: forward 59-
TGGGAAGCTGGTCATCAAC-39, reverse 59-GCATCACCC-
CATTTGATGTT-39. Quantification of -fold inductions over
untreated samples was performed using the mathematical model
described by Pfaffl [47].
Construction of expression vectors
Standard cloning procedures were performed throughout. To
generate tetracycline-inducible bidirectional promoter driven
expression plasmids encoding the rgp130/rLIFR combination or
the rgp130/rOSMR combination, we first cloned the cDNAs for
each receptor using total RNA extractions from JTC-27 rat
hepatoma cells. Upon reverse transcription, the cDNA was used to
amplify the complete coding sequence of each receptor using
specific primers containing restriction sites flanking the start or
stop codon and the PCR Extender System (5 PRIME). The
rgp130 amplicon was digested with AgeI and NotI fast digest
enzymes (Fermentas) for 30 minutes at 37uC. The rOSMR and
rLIFR amplicons were digested with SbfI and FseI (New England
Biolabs) for 4 hours at 37uC. After gel purification the fragments
were ligated stepwise into the plasmid pBO (kindly provided by
Dr. C. Haan, Luxembourg) which contains a tetracycline
responsive bidirectional promoter to allow simultaneous transcrip-
tion of two receptor cDNAs and a hygromycin B resistance
cassette to allow selection of stable cell lines [48]. Thereby pBO-
rgp130/rLIFR or pBO-rgp130/rOSMR was generated. The
integrity of all constructs was verified by DNA sequence analyses
(Eurofins MWG).
Stable transfection of murine Ba/F3 cell line
The murine pre-B cell line Ba/F3 was first transfected with the
2.5 mg of the pTetON-neo plasmid (Clontech Laboratories Inc.)
using the Nucleofector (Lonza) according to the manufacturer’s
instruction. A neomycin-resistant pool of cells was then transfected
with 2.5 mg of the pBO-rgp130/rLIFR or the pBO-rgp130/
rOSMR plasmid again using the Nucleofector. A hygromycin/
neomycin-resistant pool of cells was selected and stimulated, upon
overnight induction of the receptor expression with 0.5 mg/ml
doxycycline, with 10 ng/ml hLIF, 20 ng/ml hOSM, mOSM or
rOSM for 15 min.
Proliferation assay
Proliferation of stably transfected Ba/F3-hgp130/hOSMR [44]
in response to hOSM or rOSM was analyzed using the
colorimetric proliferation assay reagent WST-1 from Clontech.
Cells were seeded at a concentration of 16104 per 96-well and
treated with indicated concentrations of hOSM or rOSM for 48 h.
After the incubation period, 10 ml premixed WST-1 reagent were
added to every well. After 4 h incubation at 5% CO2 and 37uC in
water-saturated atmosphere, absorbance was measured at 450 nm
and 660 nm using a Multiskan EX Microplate Photometer
(Thermo Fisher Scientific Inc.). Proliferation assay results were
calculated by subtracting the A660 value from the A450 value.
Statistical analysis
All data are given as mean 6 S.E.M. using a paired, two-tailed
Student’s t-test. A value of p,0.05 was considered statistically
significant. Densitometric units obtained for phosphorylated
proteins were normalized to the loading control and either the
rOSM- or the hOSM-stimulated sample was set to 100.
Figure 7. Differences in the BC loop of human, murine and rat OSMmight be responsible for the divergent receptor usage. A, Model
structure of mOSM (amino acids 25–205 of NP_001013383.1, orange) and rOSM (amino acids 26–207 of NP_001006962.1, green) using the solved
crystal structure of human OSM (PDB entry code: 1EVS, red) as template. For molecular modeling and graphic representation the SWISS-MODEL-
Server [49,50,51] and PyMOL (DeLano, W.L. (2002) The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA, USA) were used. B,
Sequential alignment of murine, rat and human OSM. A fold recognition algorithm was used to generate the sequential alignment (ProHit package,
ProCeryon Biosciences GmbH, Salzburg, Austria). Asterisks indicate identical amino acid residues in all three species. Boxes denote helical regions and
bars indicate regions in the human OSM involved in the site 3 binding site.
doi:10.1371/journal.pone.0043155.g007
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Supporting Information
Figure S1 Comparison of hLIF, hOSM, mOSM and
rOSM activated signaling pathways in primary neonatal
rat cardiac fibroblasts (NRCFB). Cells were treated with
10 ng/ml hLIF, hOSM, mOSM or rOSM for 15 min. The
phosphorylation levels of STAT1, STAT3 and ERK1/2 were
detected via Western blot analysis. The blots were stripped and
reprobed with antibodies recognizing the proteins irrespective of
their phosphorylation status. Additionally, an a-tubulin loading
control was included.
(TIF)
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